Moderna Inc says its COVID-19 vaccine booster that targets both the original coronavirus strain and Omicron produces a better immune response against the variant than its original vaccine.
Subscribe now for unlimited access.
or signup to continue reading
The booster raised virus-neutralising antibodies by eight-fold in a study.
The vaccine was generally well-tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 micrograms level.
"We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer," Chief Executive Stephane Bancel said in a statement.
Share of Moderna were up 2 per cent in premarket trading.
Australian Associated Press